Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 8/20 | 0.44 |
| ▸ | ATF1 | P18846 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043503 | 0.84 | PDK1 (0.51) | NR1H4PDK1ATF1NFKB1S1PR1 | |
| SCHEMBL4582467 | 0.83 | BLM (0.44) | PDK1S1PR1MAPTCETP | |
| SCHEMBL3061617 | 0.83 | MAPK14 (0.50) | TSHRGAANR1H4MAPK14PDK1 | |
| SCHEMBL4581453 | 0.83 | S1PR1 (0.47) | NR1H4PDK1S1PR1MAPTPPARG | |
| SCHEMBL3065041 | 0.82 | TSHR (0.56) | TSHRGAANR1H4MAPK14PDK1 | |
| SCHEMBL3057341 | 0.80 | TSHR (0.59) | TSHRGAANR1H4MAPK14PDK1 | |
| SCHEMBL3053508 | 0.79 | TSHR (0.48) | TSHRGAAMAPK14PDK1ACHE | |
| SCHEMBL3065531 | 0.78 | TSHR (0.54) | TSHRGAANR1H4MAPK14PDK1 | |
| SCHEMBL28786186 | 0.78 | BLM (0.42) | PDK1S1PR1MAPTCETP | |
| SCHEMBL3060251 | 0.78 | TSHR (0.71) | TSHRGAANR1H4MAPK14PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | TSHR 384/4885GAA 1212/4885NR1H4 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.